Shom Goel, MD, PhD, on Use of CDK4/6 Inhibitors in Breast Cancer to Enhance Antitumor Immunity

Posted: Thursday, January 10, 2019

Shom Goel, MD, PhD, of the Dana-Farber Cancer Institute, discusses preclinical data that suggest CDK4/6 inhibitors enhance antitumor immunity, a phenomenon that might help improve outcomes for people with advanced disease.